

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended). A method for enhancing functional neuronal recovery in an individual suffering from
~~inhibiting neuronal secondary neuronal degeneration, or for~~
~~promoting nerve regeneration, caused by the neurodegenerative~~
effects of an injury, disease, disorder or condition that has
caused primary neuronal damage in the central nervous system
(CNS) or peripheral nervous system (PNS),~~or for protecting~~
~~nerves from~~of that individual, or in an individual having
neurodegeneration caused or exacerbated by glutamate toxicity,
~~which comprises~~or in an individual having a psychosis or
psychiatric disorder selected from the group consisting of an
anxiety disorder, a mood disorder, schizophrenia or a
schizophrenia-related disorder, drug use and dependence and
withdrawal, and a memory loss or cognitive disorder,
comprising administering to an~~the individual in need thereof~~
an amount of poly-Glu,Tyr effective to ~~inhibit neuronal~~
~~secondary degeneration, or to enhance functional neuronal~~
recovery in the individual~~nerve regeneration, in the CNS or~~
~~PNS, or to protect nerves from glutamate toxicity.~~

2 (Currently Amended). A method in accordance with claim 1, wherein the individual ~~in need~~ is one suffering from secondary neuronal degeneration caused by the neurodegenerative effects of an injury, disease, disorder or condition that has caused primary neuronal damage in the CNS or PNS of that individual, and wherein said administering step comprises administering poly-Glu,Tyr in an amount effective to reduce the secondary neurodegeneration at the site.

3. (Currently Amended). A method in accordance with claim 2, wherein the individual ~~in need~~ is one suffering from an injury that has caused primary neuronal damage.

4 (Original). A method in accordance with claim 3, wherein said injury is selected from the group consisting of spinal cord injury, closed head injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke, cerebral ischemia, optic nerve injury and injury caused by tumor excision.

5 (Original). A method in accordance with claim 4, wherein said injury is spinal cord injury.

6 (Original). A method in accordance with claim 4, wherein said injury is ischemic stroke.

7 (Previously Presented). A method in accordance with claim 2, wherein said injury, disease, disorder or

condition is a neurodegenerative disease, disorder or condition associated with the eye.

8 (Previously Presented). A method in accordance with claim 7, wherein said neurodegenerative disease, disorder or condition associated with the eye is non-arteritic optic neuropathy or a disease associated with elevated intraocular pressure.

9 (Cancelled).

10 (Currently Amended). A method in accordance with claim 1, wherein ~~said the individual in need~~ is one having ~~an injury, disease, disorder or condition~~ neurodegeneration caused or exacerbated by glutamate toxicity, and wherein said administering step comprises administering poly-Glu,Tyr to the individual ~~in need~~ in an amount effective to ameliorate the neurodegeneration caused or exacerbated by glutamate toxicity.

11 (Currently Amended). A method in accordance with claim 10, wherein ~~said injury, disease, disorder or condition~~ the neurodegeneration caused or exacerbated by glutamate toxicity is associated with a neurodegenerative disease, disorder or condition.

12 (Previously Presented). A method in accordance with claim 11, wherein said neurodegenerative disease, disorder or condition is selected from the group consisting of senile dementia, Parkinson's disease, facial nerve (Bell's)

palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS), and Creutzfeldt-Jakob disease.

13 (Currently Amended). A method in accordance with claim 10, wherein ~~said injury, disease, disorder or condition~~the neurodegeneration caused or exacerbated by glutamate toxicity is associated with a peripheral neuropathy.

14 (Original). A method in accordance with claim 13, wherein said peripheral neuropathy is selected from the group consisting of adrenomyeloneuropathy, amyloid polyneuropathy, chronic ataxic neuropathy, diabetic neuropathy, carpal tunnel syndrome, intervertebral disc herniation, giant axonal neuropathy, ischemia, vitamin deficiency, malabsorption syndromes, alcoholism, a toxic neuropathy caused by organophosphates, a neuropathy associated with a disease or disorder selected from the group consisting of ataxia telangiectasia, Charcot-Marie-Tooth disease, obstructive lung diseases, Fabry's disease, Friedreich ataxia, hypoglycemia, IgG or IgA gammopathies, lipoproteinemia, Refsum's syndrome, and Sjogren-Larsson syndrome, or a polyneuropathy associated with various drugs or with hypoglycemia.

15 (Currently Amended). A method in accordance with claim 10, wherein ~~said injury, disease, disorder or condition~~the neurodegeneration caused or exacerbated by

glutamate toxicity is associated with epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, or opiate tolerance and dependence.

16 (Currently Amended). A method in accordance with claim 1, wherein the individual ~~in need~~ is one having a psychosis or psychiatric disorder selected from the group consisting of an anxiety disorder, a mood disorder, schizophrenia or a schizophrenia-related disorder, drug use and dependence and withdrawal, and a memory loss or cognitive disorder.

17 (Currently Amended). A method in accordance with claim 16, wherein said psychosis or psychiatric disorder is an anxiety disorder selected from the group consisting of a phobic disorder, an obsessive-compulsive disorder, a post-traumatic stress disorder, an acute stress disorder and a generalized anxiety disorder; said mood disorder is selected from the group consisting of depression, a dysthymic disorder, a bipolar disorder and a cyclothymic disorder; said schizophrenia-related disorder is selected from the group consisting of brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; said drug use and dependence is selected from the group consisting of alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence,

Appln. No. 10/807,414
Amdt. dated April 20, 2007
Reply to Office action of January 22, 2007

and phencyclidine use; and said memory loss disorder is amnesia or memory loss associated with a disease or disorder selected from the group consisting of Alzheimer's type dementia, non-Alzheimer's type dementia, Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

18 (Previously Presented). A method in accordance with claim 16, wherein said psychosis or psychiatric disorder is schizophrenia.

19 - 72 (Cancelled).